A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia
- 1 December 2014
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 14 (6) , 534-539
Abstract
No abstract availableKeywords
Funding Information
- Gemin X Pharmaceuticals, Inc
- Teva
This publication has 22 references indexed in Scilit:
- How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic SyndromesHematology-American Society Hematology Education Program, 2010
- Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndromeExperimental Hematology, 2007
- The Myelodysplastic Syndromes: Diagnosis and TreatmentMayo Clinic Proceedings, 2006
- Simultaneous Demonstration of Clonal Chromosome Abnormalities and Apoptosis in Individual Marrow Cells in Myelodysplastic SyndromeInternational Journal of Hematology, 2004
- Expression of tumor necrosis factor–related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesisBlood, 2001
- The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDSBlood, 2000
- Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in ‘good’ versus ‘poor’ prognosis patients and correlation with apoptosis-related genesLeukemia, 1999
- MyelodysplasiaNew England Journal of Medicine, 1999
- Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessmentLeukemia, 1997
- Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cellsBlood, 1996